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A B S T R A C T
The oral administration of solid dosage forms is the commonest method to achieve systemic therapy and relies on the drug’s solubility in human intestinal fluid (HIF),
a key factor that influences bioavailability and biopharmaceutical classification. However, HIF is difficult to obtain and is known to be variable, which has led to the
development of a range of simulated intestinal fluid (SIF) systems to determine drug solubility in vitro. In this study we have applied a novel multidimensional
approach to analyse and characterise HIF composition using a published data set in both fasted and fed states with a view to refining the existing SIF approaches. The
data set provided 152 and 172 measurements of five variables (total bile salt, phospholipid, total free fatty acid, cholesterol and pH) in time-dependent HIF samples
from 20 volunteers in the fasted and fed state, respectively. The variable data sets for both fasted state and fed state are complex, do not follow normal distributions
but the amphiphilic variable concentrations are correlated. When plotted 2-dimensionally a generally ellipsoid shaped data cloud with a positive slope is revealed
with boundaries that enclose published fasted or fed HIF compositions. The data cloud also encloses the majority of fasted state and fed state SIF recipes and
illustrates that the structured nature of design of experiment (DoE) approaches does not optimally cover the variable space and may examine media compositions that
are not biorelevant. A principal component analysis in either fasted or fed state in combination with fitting an ellipsoid shape to enclose the data results in 8 points
that capture over 95% of the compositional variability of HIF. The variable’s average rate of concentration change in both fasted state and fed state over a short time
scale (10 min) is zero and a Euclidean analysis highlights differences between the fasted and fed states and among individual volunteers. The results indicate that a 9-
point DoE (8 + 1 central point) could be applied to investigate drug solubility in vitro and provide statistical solubility limits. In addition, a single point could
provide a worst-case solubility measurement to define the lowest biopharmaceutical classification boundary or for use during drug development. This study has
provided a novel description of HIF composition. The approach could be expanded in multiple ways by incorporation of further data sets to improve the statistical
coverage or to cover specific patient groups (e.g., paediatric). Further development might also be possible to analyse information on the time dependent behaviour of
HIF and to guide HIF sampling and analysis protocols.
1. Introduction
Oral drug administration is the favoured route based around patient
preference and compliance with solid oral dosage forms the most
common pharmaceutical product type. Since solids are not absorbed
from the gastrointestinal tract oral systemic therapy requires the solid
drug particles to dissolve prior to molecular passage of the drug across
the gastrointestinal mucosa and transit through the portal venous
system via the liver to the general circulation. Oral bioavailability is
therefore controlled by a drug’s solubility and dissolution in the gas-
trointestinal environment, permeability through the gastrointestinal
mucosa and potential for enzymatic degradation in the gastrointestinal
lumen, mucosa or liver [1]. Drug solubility in the gastrointestinal en-
vironment is therefore a key factor controlling bioavailability and has
been incorporated into theoretical and practical biopharmaceutical
concepts for example the Absorption Potential (AP) [2], Maximum
Absorbable Dose (MAD) [3], Biopharmaceutical Classification System
(BCS) [4] and Developability Classification System (DCS) [5,6]. This
has led to a focus on gastrointestinal drug solubility during develop-
ment [7–9] and a recognition that determination of the value either by
computation or experimentation is a key stage. However, the current
experimental methods available to determine solubility are not ade-
quate [10] to permit in vivo prediction of average solubility and its
variability from in vitro measurement and further development is
warranted.
Drug solubility in an aqueous solution is controlled by the solution’s
composition. For example, the effect of solution pH on the solubility of
ionisable drugs through application of the Henderson-Hasselbalch re-
lationship is well established [1,11]. However, gastrointestinal fluid is a
heterogeneous system with changes in pH and also the variable pre-
sence and concentration of additional components either endogenously
excreted [12] or added via ingestion of food [13]. Gastrointestinal fluid
is therefore a complex system containing for example electrolytes, bile
salts, lipids and lipid digestion products, cholesterol, proteins, enzymes
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plus other components and will also vary depending upon the anato-
mical location (stomach vs small intestine vs colon) [14] and the
prandial state of the individual [15]. In addition, the gastrointestinal
tract is dynamic and the composition is continuously changing through
a cycle of fasted and fed states superimposed upon the inherent biolo-
gical variability of human subjects [16]. In order to assess the impact of
the complex and variable composition of gastrointestinal fluids on drug
solubility and therefore absorption, two general approaches have been
adopted: the aspiration of human intestinal fluid (HIF) [12] for direct
solubility measurements or the development of simulated intestinal
fluids (SIF) based on the aspirated samples [17].
HIF aspiration requires oral intubation, determination of the ca-
theter’s anatomical location, followed by sample collection [15]. Sev-
eral groups have developed sampling approaches [12,18,19] and de-
termined the solubility of a range of drugs in both fasted [20] and fed
[13] state HIF samples. These studies have demonstrated the variability
of HIF composition between volunteers [21] and between intestinal
regions [14,22]. HIF is cited as the most relevant system for the conduct
of solubility studies and referred to as the “gold standard” [6,14],
however, its use is restricted by the difficulty of sampling, the small
fluid volumes obtained and the inherent variability.
In order to circumvent the issues associated with HIF, SIF have been
developed employing physiologically relevant physicochemical condi-
tions (e.g. pH and osmolality) and concentrations of HIF components
(e.g. bile salt and phospholipid) [17,23]. In early studies, the SIF per-
formance with respect to dissolution or solubility of poorly soluble
drugs was compared directly with HIF [18,19] in order to refine and
develop optimized SIF compositions. SIF media composition has sub-
sequently been developed by multiple groups to improve performance
with respect to HIF and several compositions are available [24–26].
This refinement continues and a recent publication proposed a further
modification of fasted simulated intestinal fluid (FaSSIF) [27] based
around an improved solubility determination of ten poorly soluble
drugs when compared to literature solubility values in HIF. Multiple
similar studies have also been conducted for fed state simulated in-
testinal fluid (FeSSIF) [17,23,26,28,29] with five variants present in the
literature. A recent review covers the development and recipes of var-
ious types of simulated fluids [24].
As the available SIF aim to mimic the average composition of fasted
or fed HIF, they cannot be used to assess the sensitivity of a drug’s
solubility to the high variability in HIF composition. To examine the
impact of media composition on solubility, statistical investigations of
media composition, guided by the available literature information [15]
on HIF and SIF, have been performed. Typical media variables (fasted –
bile salt, lecithin, buffer, salt, pH, enzyme and fatty acid; fed as fasted
plus mono-glyceride) and ranges were employed and a design of ex-
periment (DoE) approach applied to study solubility using a range of
poorly soluble drugs in either fasted or fed states. For the fasted state
two approaches have been adopted: a fractional factorial design in-
cluding 7 variables with 2 concentration levels requiring 66 experi-
ments (per drug examined) [30] or a 5 variable design requiring 24
experiments [31]. In the fed state a single study has applied a D-optimal
design with 8 variables and 2 concentration levels requiring 92 ex-
periments [32]. Further studies have examined the application of
smaller experiment number DoE systems [33,34] that combine fasted
and fed states, culminating in a reduced scale 9 point DoE [35]. These
studies indicated that solubility varied in a drug dependent manner by
up to three orders of magnitude and drug behaviour could be broadly
classified according to ionisation characteristics (acidic, basic and non-
ionisable). They also identified the key media variables influencing
solubility and some variables e.g. enzyme and salt that had limited or
no solubility impact. For acidic drugs, the key solubility driver was pH
with limited impact from bile salt, lecithin and fatty acid. Basic and
non-ionisable drugs displayed a different behaviour with pH, bile salt,
lecithin and fatty acid contributing equally to solubility and in the fed
state to a lesser extent mono-glyceride. The results also revealedTa
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significant interactions between the variables (e.g. pH and fatty acid)
influencing solubility and the presence of drug specific behaviour in the
systems.
The approaches presented above for the in vitro determination of
intestinal solubility and investigation and refinement of SIF recipes
have a range of limitations. The development of SIF composition based
on drug solubility in individual, multiple or pooled HIF samples, will be
influenced by the already extensively covered issue of HIF variability,
the inability to link solubility to media composition and the limitations
of fluid aspiration. The DoE approach is too experimentally intensive
for routine application and is likely to contain media systems that will
have limited biorelevance, due to the statistical design (i.e., linking
high and low variable concentrations (for example bile salt and phos-
pholipid)). The use of a single point in vitro solubility measurement in
either HIF or SIF is also likely to be limited. Due to the compositional
variability, an individual HIF sample cannot be related to a likely po-
pulation value, while a HIF pool (number of samples/donors depen-
dent) aims to determine solubility in average conditions. However, a
single solubility determination using either HIF or SIF will not provide
any information on the solubility variability, which the DoE and related
studies [32,36] have shown is inherently present in these systems.
Recently, a systematic study was published in which duodenal HIF
samples from 20 subjects in fasted and fed states were collected and
comprehensively analysed [21]. The results of this study highlight the
inherent variability of HIF and provided time and prandial state based
concentration data on multiple variables (pH, bile salt, phospholipid,
cholesterol, free fatty acid and glycerides), some of which have been
investigated in the DoE studies and various SIF recipes. In this paper,
we have mathematically examined this data set using a novel multi-
dimensional approach (each variable representing one dimension) to
provide an improved understanding of the variation within the total
data set, individual volunteer data sets, and to determine possible
concentration correlations between media components. The aim was to
explore the DoE limitation of linking high and low variable con-
centrations, to determine potential SIF recipes with improved relevance
to HIF and to provide statistical boundaries for the SIF media that could
link in vitro measurement to potential in vivo coverage.
2. Data and analysis methods
2.1. Data
The data set analysed in this paper has been previously published
[21] and readers should consult this paper for details of the clinical
protocol, biochemical analysis methods, initial discussion of the results
and comparison with previous literature studies. In brief, HIF was
collected from 20 healthy volunteers (equal number of male and female
subjects, age range 18–31, BMI range 19–25 kg/m2) in both fasted and
fed state. After an overnight fast (> 12 h), a nasogastric catheter was
inserted and volunteers were administered 250 ml water prior to fasted
state sampling every 10 min for a 90 min period. Subsequently, 400 ml
Ensure Plus was ingested followed by 250 ml of water after 20 min to
represent the fed state with sampling every 10 min for a 90 min period
[21]. The samples were analysed for pH, phospholipids, cholesterol,
bile salts, lipid content, pancreatic lipase, phospholipase A2 and non-
specific esterase activity. For the purposes of this analysis individual
bile salt or fatty acid species concentrations were summed to provide a
total concentration of bile salts and free fatty acids; the enzymatic va-
lues were not considered. The latter have been previously shown not to
impact solubility during an equilibrium analysis [30,32] and were
therefore excluded leaving five variables pH, total bile salt, phospho-
lipid, free fatty acid and cholesterol per sample with volunteer and
sample time as additional variable.
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2.2. Analysis methods
2.2.1. Statistics
Basic statistics and data set comparisons were performed using
Prism8. Correlation statistics were performed using IBM SPSS Statistics
v25. The Euclidean centre point in 5-dimensional space (each variable
is one dimension) in each data set was calculated using FilemakerPro
Advanced 17, this point does not assume a distribution function and is
different from the mean and median variable values which are only
calculated in one dimension. Two dimensional graphs were plotted
using DataGraph v4.4. All the preceding software run on a Mac
OS X 10.13.6 computer.
2.2.2. Multidimensional analysis
The aim of this analysis was to summarise the HIF composition data
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Fig. 1. Fasted and fed matched data sets. fed
state; fasted state, statistical measures indicated
by labels.
Table 3
Fasted State Variable Correlation.
Variable Time
Time – Bile Salt
Bile Salt NC – Phospholipid
Phospholipid NC 0.634** – Free
Fatty
Acid
Free Fatty Acid NC 0.463** 0.314** – Cholesterol
Cholesterol 0.170* 0.757** 0.519** 0.282** – pH
pH 0.269** NC NC 0.247** NC –
NC No significant correlation;
** Correlation significant at P < 0.01;
* Correlation significant at P < 0.05
Table 4
Fed State Variable Correlation.
Variable Time
Time – Bile Salt
Bile Salt NC – Phospholipid
Phospholipid NC 0.579** – Free Fatty Acid
Free Fatty Acid −0.247** 0.339** 0.446** – Cholesterol
Cholesterol −0.155* 0.313** 0.414** NC – pH
pH −0.321** 0.402** 0.281** 0.332** NC –
NC No significant correlation;
** Correlation significant at P < 0.01;
* Correlation significant at P < 0.05
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using points from a bounding ellipse with the general form:
− + −
+
− − −
=
x h α y k α
a
x h α y k α
b
(( )cos ( )sin ) (( )sin ( )cos ) 1
2
2
2
2
The centre of the ellipse is h k( , ), which are the medians for each of
the variables plotted. Both a and b are the radii of the ellipse in
the × and y direction respectively. The values of a and b are calculated
using the eigenvalues from the covariance matrix of x and y, and are
equivalent to the variability in the direction of each of x and y around a
fitted line, and have been scaled by 1.5 to cover approximately 90% of
the distribution of points. The angle α is the angle of rotation, which
was obtained using information about correlation via the eigenvectors.
The parameters for the ellipse between each pair of variables is shown
in Table 5 and 6 and visualy in Figs. 4 and 5.
When looking at more than two variables, principal components
analysis (PCA) was used in order to extract the information required to
construct a set of points which span the space of the observations. The
rotation matrix computed as part of the PCA was used to assess the
slope of the ellipse axis in each of the dimensions, resulting in a rotation
around the centre of the ellipse which was represented by the set of
medians for each of the variables in the data set. The PCA variances
indicate the variability in each of the rotated dimensions, and these
were scaled by 1.5, as before, to provide sensible bounding limits. Using
PCA means that some smaller subset of points could be used assuming
that the variability explained by the firstm components is large enough.
A visual representation of these points is shown in Figs. 6 and 7, with
further discussion in Section 3.
3. Results and discussion
3.1. Initial data analysis
Based on the sampling protocol, the maximum number of HIF
samples in the study in either fasted or fed state is 180, which would
Table 5
Matched Fasted Data.
Principal Component Analysis Results
Component 1 Component 2 Component 3 Component 4 Component 5
BS 0.475 0.212 0.854
PL 0.558 0.643 −0.481 −0.208
FFA 0.194 0.363 0.846 −0.326
Chol 0.653 −0.674 −0.346
pH 0.995
Variation 42.4% 22.6% 18.5% 12.9% 3.6%
Ellipse parameters for each pair of factors for the fasted data.
h k a b α
BS & PL 1.25 −0.48 2.01 0.94 55.26°
BS & FFA 1.25 0.55 1.53 0.98 34.37°
BS & Chol 1.25 −2.62 2.16 0.89 57.66°
BS & pH 1.25 1.93 1.38 0.23 1.10°
PL & FFA −0.48 0.55 1.80 1.09 19.40°
PL & Chol −0.48 −2.62 2.21 1.30 50.08°
PL & pH −0.48 1.93 1.74 0.23 0.02°
FFA & Chol 0.55 −2.62 1.91 1.15 79.13°
FFA & pH 0.55 1.93 1.19 0.21 4.55°
Chol & pH −2.62 1.93 1.89 0.23 0.95°
Table 6
Matched Fed Data.
Principal Component Analysis Results
Component 1 Component 2 Component 3 Component 4 Component 5
BS 0.270 0.515 0.525 0.620
PL 0.250 0.532 0.256 −0.768
FFA 0.102 0.568 −0.800 0.160
Chol 0.924 −0.357 −0.135
pH −0.999
Variation 40.4% 27.3% 18.6% 11.8% 1.9%
Ellipse parameters for each pair of factors for the fasted data.
h k a b α
BS & PL 2.27 1.39 1.32 0.59 42.66°
BS & FFA 2.27 3.11 1.20 0.90 46.84°
BS & Chol 2.27 −0.56 1.91 0.99 77.25°
BS & pH 2.27 1.84 1.05 0.09 2.30°
PL & FFA 1.39 3.11 1.22 0.80 50.15°
PL & Chol 1.39 −0.56 1.90 0.94 78.83°
PL & pH 1.39 1.84 0.99 0.10 1.99°
FFA & Chol 3.11 −0.56 1.87 1.07 87.86°
FFA & pH 3.11 1.84 1.07 0.10 2.10°
Chol & pH −0.56 1.84 1.87 0.10 0.27°
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provide a total of 900 individual variable measurements. As sampling
was not always feasible the number of samples achieved was 162 in the
fasted state and 175 in the fed state; this has been classed as the full
data set. As not all of these samples could be fully analysed, only 152
fasted state samples and 172 fed state samples contained a matched
measurement of all five variables (i.e. same subject and sample time
point with measurement of pH, total bile salt, phospholipid, free fatty
acid and cholesterol); this has been classed as the matched data set.
The basic statistics for the fasted state data sets (full and matched)
are presented in Table 1 with fed state data in Table 2. No variables
present a normal distribution as assessed by the Kolmogorov-Smirnov
test and only two, phospholipid in the fasted and bile salt in the fed,
have log normal distributions. This result, in combination with the
calculated Skewness and Kurtosis values, indicates that these data sets
are complex to describe and analyse using simple statistics see Fig. 1
and supplementary data Figure S1. Since the matched data set is a
subset of the full data set, a non-parametric Mann-Whitney comparison
was performed for each variable in the fasted and fed states. No sig-
nificant difference (P < 0.05) between the full and matched data sets
was found indicating that the selection and number reduction has not
impacted on the data and all further analyses have been performed
using the matched data sets only.
A comparison of the fasted and fed state data sets indicates a sig-
nificant difference between the two states (supplementary data Figure
S1) for the five variables, which is expected based on published lit-
erature [15,37]. The matched data set provides a cloud of points con-
taining five variables (concentration measurements of bile salt, phos-
pholipid, free fatty acid and cholesterol and pH), or dimensions, which
cannot be presented using a single 2-dimensional graph. To visualize
the individual data points 2-dimensionally the bile salt concentration (a
universally measured HIF property [12]) has been chosen as a constant
x-axis with the four remaining variables on the y-axis. This produces a
set of four graphs to represent all variables (Fig. 1) with a log/log scale
chosen (with the exception of pH) so that the points sit within the axes.
This permits easier data visualisation as a cloud and highlights differ-
ences and overlaps between the fasted and fed states (Fig. 1). In general
the mean value tends towards the higher concentration end of the
distribution with the median and Euclidean centre points visually more
representative of the distribution centre. Although the difference be-
tween the mean and median may be exaggerated by the use of a log–log
plot the values are presented in Table 1 and 2 for comparison. Fig. 1
also illustrates that to apply standard distribution statistics, for example
mean with a standard deviation or median with a centile is not ap-
propriate since in general the distributions have an ellipsoid shape with
a slope or positive correlation (see section 3.2).
3.2. Amphiphilic variable correlations
Analysis of the data sets for correlations between the variables is
presented in Table 3 for the fasted state and Table 4 for the fed state. In
the fasted state data there is a positive correlation between all the
amphiphilic variables (bile salt, phospholipid, free fatty acid and cho-
lesterol) with mixed correlations for pH. This is also highlighted in the
principal component analysis (Tables 5 and 6), where pH is a separate
component. In the fed state data there is a similar positive correlation
between all the amphiphilic variables (with the exception of free fatty
acid with cholesterol) and the amphiphilic variables with pH (except
cholesterol). The relationship between fasted and fed state and con-
centrations of bile salt with phospholipid is well established in the lit-
erature [13,21,38–40] and a consequence of gastrointestinal physiology
Dressman
Galia&Vertzoni
Pedersen
Sunesen-Low
Sunesen-High
Jantratid
Brinkmann
Persson
Clarysse
Heikkila
Holmstock
Stappaerts
Litou30
Ph
os
ph
ol
ip
id
 (m
M)
0.01
0.1
1
10
Total Bile Salt (mM)
0.1 1 10
Litou30Fr
ee
 F
at
ty
 A
ci
d 
(m
M
)
0.1
1
10
Total Bile Salt (mM)
0.1 1 10
Heikkila
Litou30
C
ho
le
st
er
ol
 (m
M
)
10?3
10?2
10?1
1
Total Bile Salt (mM)
0.1 1 10
Lindhal
Pedersen
Persson
Kalantzi
Clarysse
Dressman
Galia&Vertzoni
Pedersen
Sunesen-Low
Sunesen-High
Jantratid
Brinkmann
Litou30
pH
2
3
4
5
6
7
8
9
Total Bile Salt (mM)
0.1 1 10
Fig. 2. Fasted matched data set concentrations with
literature HIF measurements, SIF recipes and Design
of Experiment Points. fasted data. o HIF literature
reference data, curved label, Clarysse [13]; Heikkila
[42]; Holmstock [43]; Kalantzi [37]; Lindhal [12];
Litou [44] ; Pedersen [19]; Persson [40]; Stappaerts
[45]. ● SIF literature reference data, straight label,
Brinkmann-Trettenes [58]; Dressman [17]; Galia
[23]; Jantratid [59]; Pedersen [18,19]; Sunesen
[48]; Vertzoni [28].■ Design of Experiment sample
points from Khadra [30]; □Design of Experiment
sample points from Madsen [31]. NB no SIF recipes
contain free fatty acid or cholesterol.
K. Pyper, et al. European Journal of Pharmaceutics and Biopharmaceutics 153 (2020) 226–240
231
[41]. The intra-state correlation of amphiphile concentrations is ex-
pected based on the fasted and fed correlation but it is not widely re-
ported in the literature, although multiple studies (see section 3.3) have
measured these values. This positive correlation of the amphiphilic
variables indicates that the use of statistical design of experiment pro-
tocols [30–34] that link low and high concentration values in order to
investigate a variables solubility contribution is likely to examine media
compositions that are not biorelevant (see section 3.5).
3.3. Comparison with literature HIF analysis values
The fasted and fed state data sets have been plotted in Figs. 2 and 3
along with available literature data on measured HIF composition.
Available literature HIF composition data in either the fasted (Clarysse
[13]; Heikkila [42]; Holmstock [43]; Kalantzi [37]; Lindhal [12]; Litou
[44]; Pedersen [19]; Persson [40]; Stappaerts [45]) or fed (Clarysse
[13]; Holmstock [43]; Kalantzi [37]; Persson [40]; Stappaerts [45])
state has been plotted on the figures. Note that measurement of vari-
ables across these studies is not consistent, several studies used pooled
samples from multiple and varying numbers of subjects and sampling
protocols, for example pre-administration of water. Variability in the
fed state related to the nature of the food intake will also be present in
the literature data [46,47]. In general, even with these limitations, the
literature results fit within the data cloud in this study, indicating that
the data employed in this analysis is comparable to published literature,
a more detailed comparison is available in the original publication [21].
However, the literature results are spread throughout the space, which
correlates with the existing conclusion on the variable nature of HIF
(both fasted and fed), implying that single HIF samples cannot be
considered representative for the entire intestinal fluid compositional
data space.
3.4. Comparison with literature SIF recipes
The literature contains multiple references and recipes for simulated
media [24,30,32] that can be superimposed on the data sets, see Figs. 2
and 3. Note a comparison is only present where the simulated media
recipe employs the variables measured in this study.
The fasted state comparison is only based around bile salt, phos-
pholipid and pH, however the majority of recipes contain additional
components, for example buffer (phosphate or tris/maleate), salt (so-
dium or potassium chloride), pancreatin and use physicochemical
properties osmolality or surface tension as a characteristic. Some of
these latter recipe variables have been determined to have no sig-
nificant impact on equilibrium solubility [30–32] and are therefore not
critical, assuming that specific issues, e.g. a common ion or poorly so-
luble salt effect, are not present for the drug under measurement.
The fasted state bile salt/phospholipid comparison (Fig. 2) indicates
that the recipes are spread throughout the measured space with a
general tendency to the centre and with a high phospholipid con-
centration. One system [29] is near the lower end of the distribution
space and one of the recipes [28] matches the Euclidean centre. In some
cases the difference between the median and Euclidean centres is minor
[18,23,48]. Overall there is an excellent match between central dis-
tribution value of this study and the multiple SIF media recipes, al-
though different experimental methods were applied to determine the
recipe. The bile salt/pH comparison is similar however with a reduced
variation between the recipes and several using a pH value that is close
to the Euclidean centre.
The fed state comparison is based around bile salt, phospholipid,
free fatty acid and pH and a similar issue with respect to recipe vari-
ables is evident [32]. For the fed recipes with bile salt and phospholipid
there is a greater consistency between the researchers, which results in
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a lower coverage of the data space, a tendency to a high bile salt but
low phospholipid or free fatty acid and for pH a large variation. With
the exception of the bile salt/phospholipid ratio where some systems
are close to the mean, in the majority of cases the recipe values do not
reflect the central data space values.
In general, all recipes are within the measured data space and reflect
the scientific design approaches adopted to determine the recipes based
on measurements of individual or pooled HIF samples and the adjust-
ment of SIF composition to provide a similar measured drug solubility
to a HIF determination. However, the differences between the fed re-
cipes and the central data set values indicate that further refinement of
these systems is possible. The results also illustrate that the use of a
single measurement point based on any of the recipes is not able to
determine a drug solubility value that would be representative of the
entire HIF data space [49].
3.5. Comparison with DoE investigations
A similar comparison for the Design of Experiment based
investigations of simulated media are presented in Figs. 2 and 3 for the
fasted and fed states respectively. The structured statistical nature of
the DoE is evident in the point distribution along with the limitations
(section 3.3) of applying standard distribution statistics to examine HIF
space. For example in Figs. 2 and 3 the high bile salt/low pH value
(lower right DoE point of Khadra [30] or Madsen [31]) is out with or on
the extremes of the data distribution and therefore of limited bior-
elevance. In the fasted state the bile salt/phospholipid relationship is
excellent but this is not the case for free fatty acid or pH. In the former
the high values applied are too high, although the low values are ap-
propriate. For pH the Khadra [30] values applied are too low with the
Madsen [31] values providing a better coverage. In the fed state for all
measurements the coverage is not optimal with DoE points obviously
outside the measured HIF range or failing to include areas of the range
[32]. This deficiency is in part due to the use of limited literature HIF
measurements [15] at the time of study design [30,32].
In addition, Figs. 2 and 3 highlight the limitations of applying a
structured DoE analysis based on a central point and a distribution with
high and low values. This approach is not applicable were the variable
Fig. 4. Fasted data calculated ellipses for each pair of variable measurements. Ellipse dashed line; median value.
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distributions are not normal (section 3.1) and the variables are corre-
lated (section 3.2), indicating that a tailored DoE approach is required
to remove analysis points that are not biorelevant.
3.6. Multidimensional principal component analysis and ellipsoid fitting
The principal component analysis results and the calculated ellipse
for each pair of variables are presented in Table 5 and 6 for the fasted
and fed states respectively, with a graphical representation of the el-
lipses in Figs. 4 and 5. The PCA indicates that in both fasted and fed
data sets pH is a minor contributor to the observed variation in in-
testinal fluid composition which is the opposite to the DoE solubility
analysis where pH is a major variable [30–32] influencing solubility.
Visually it can be seen from Figs. 4 and 5 that the ellipsoid approach
provides an improved data coverage and description when compared
with the DoE approach (Figs. 2 and 3) of individual variable high and
low values (see section 3.2 and 3.5).
Pairs of data points on the ellipse can be calculated along with the
percentage coverage of the data variation and these are presented in
Tables 7, with a graphical representation in Figs. 6 and 7. In the fasted
state, 4 points cover 65% of the data variation, which increases to 96%
with 8 points. In the fed state, the coverage values are 68% and 98%
respectively. The preparation of simulated media systems (either fasted
Fig. 5. Fed data calculated ellipses for each pair of variable measurements. Ellipse dashed line; median value.
Table 7
Multidimensional Principal Component.
Point* Variance Coverage
Fasted Fed
1
65.0% 67.7%
2
3
4
5
83.5% 86.3%6
7
96.4% 98.1%8
* See Figs. 6 and 7 for point values.
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or fed state) using these 8 points would therefore provide a> 95%
coverage of the potential intestinal compositions and therefore solubi-
lity values for a drug. If a lower level of coverage is required then a
reduced number of data measurements is possible, but due to the
mathematical analysis applied, this must be performed as pairs of
points (see Table 7).
The large experiment number DoE protocols [30,32] have been
successively modified to minimise the experimental load by for example
changing the design and reducing the number of variable concentra-
tions investigated [33] with the smallest protocol consisting of nine
experiments [35]. This approach reduces statistical resolution since
only the most significant factors impacting solubility are identified and
factor combination determinations are not possible. However, the so-
lubility range can be successfully identified using only nine experi-
mental points. The 8 points identified in this analysis could therefore be
supplemented with a central point to produce a nine point DoE analysis,
providing in vivo statistical limitations to the solubility range de-
termined and with the possible ability to identify major variables im-
pacting solubility. If a central point or point related to an existing SIF
recipe was also employed then comparability with previous data sets
might also be possible. This approach has caveats since existing SIF
recipes do not contain all the HIF variables analysed in this study (see
Figs. 2 and 3) along with the issue that solubility variability in simu-
lated systems is inversely proportional to the number of variables in-
cluded [36]. This will necessitate appropriate modification of the cur-
rent SIF recipes, which inevitably limits retrospective comparison. In
addition, the ellipsoid approach of determining the data cloud bound-
aries may suffer from inherent limitations since the focus is not on the
HIF zone of maximum population/point density, which will be in the
centre of the cloud. This can be mitigated as presented above by in-
cluding a central point, however it is likely that although variable
concentrations will be proportional across the space, solubility will not
[32,36] and the potential for missing solubility minima or maxima
cannot be ruled out.
The current SIF recipes are applied as single point measurements for
screening solubility during drug development [38] and also for mea-
suring solubility in order the determine DCS classification [5,6]. For
poorly soluble drugs, where pH is not a major solubility driver, [30,32]
solubility generally increases as the total amphiphile content and pH of
a system increases [36]. This analysis indicates that a single point in
either fasted or fed states with the lowest total amphiphile concentra-
tion and pH (dependent upon drug pKa considerations), for example
point 1 in Fig. 6 or 7 might represent the lowest possible intestinal
solubility. Since> 95% of the media variation (and therefore also so-
lubility variation) in terms of amphiphile concentration and pH are
higher than this point, a simulated media recipe applying these con-
ditions would determine a solubility value which represents a lowest or
worst case scenario for application in drug development studies or for
DCS classification [5,6,36]. This will be a more robust approach than a
single point solubility measurement in a simulated media recipe based
on central distribution values. In this latter measurement, the solubility
variation due to media changes for a drug will not be determined
[30,32,49], which could result in errors. A similar limitation would also
apply to sampled HIF solubility determination unless compositional
analyses were performed to assess the variable concentrations with
respect to the overall population distribution. In all cases, it would be
prudent to check that no obvious drug specific solubility effects influ-
enced the measurement.
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3.7. Time dependent variation and subject variability analysis
In both fasted and fed state, the intestinal fluid samples were col-
lected every 10 min for a 90 min period [21], which allows determi-
nation of correlations between variables with time and calculation of a
variable’s rate of change between sample points.
In the fasted state there is no time based correlation with bile salt,
phospholipid and free fatty acid but a positive correlation with
cholesterol and pH. No literature references statistically assess fasted
time based correlations and although fasted state HIF is considered
variable this result indicates that variability is not time dependent. In
the fed state there are negative correlations of time with free fatty acid,
cholesterol and pH, indicating that sample time in the fed state is im-
portant. The negative correlation in the fed state between time and free
fatty acid and cholesterol is linked to the known variation in intestinal
fluid post-feeding and the transit and digestion/absorption of intestinal
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contents [14,15,37]. It is of note that in the fed state no time based
correlation was seen for bile salt and phospholipid although time based
changes have been reported in the literature [37]; this may be due to
the relatively short (90 min) sampling duration in this study. The results
indicate that fed state HIF is time dependent [13,37] and may require
more sophisticated analysis than applied in this study.
A variables rate of change between samples are presented as violin
plots for both fasted and fed state in Fig. 8. The striking result is that the
average rate of change for all variables in either prandial state is very
close to zero although some, for example bile salt in the fasted state or
free fatty acid in the fed state exhibit a large variation. A similar ana-
lysis for this data was presented by the original investigators [21]. This
finding indicates that on a short time scale (10 min) random con-
centration fluctuations take place but there are overall compositional
limitations or boundaries (Fig. 1). The variability may be related to for
example variations in inherent subject intestinal fluid composition or
consistency, sampling and analysis variability [50], the presence of
“water pockets” [51] or catheter or peristaltic movements between
measurements. It should be noted that the results in Fig. 8 do not
analyse longer term (> 10 min) time based trends (see above) for
which a more sophisticated time based method will be required. Time
based trends are present within the fed state for physiological reasons
due to digestion and movement of materials within the tract during this
process [37,52].
It is also possible to calculate a Euclidean distance between each
time point and an average Euclidean distance per subject during the
sampling period of either the fasted or fed states (Figure S2). The results
illustrate that the fasted state has a lower Euclidean value and dis-
tribution than the fed state indicating that at each measured time point
the concentration differences between all the variables are smaller and
more consistent. In the fed state the concentration differences are
greater and the overall Euclidean distance value and distribution of
results is larger. This is possibly expected based on fed state intestinal
physiology with a larger volume of fluid, increased secretions and tract
peristalsis [53]. This increase is applicable in nearly all subjects since
the fed value is larger than the corresponding fasted.
Data for two subjects are presented for the fasted and fed states in
Figs. 9 and 10 respectively. The lower Euclidean value of subject B in
the fasted state is easily visualised since all the measurement values are
closely grouped throughout the study period whereas for subject A
there is a large movement of variable concentrations throughout the
data space. In both cases the changes do not appear to be linked to a
single variable but a combination of all variables. This difference is not
as evident in the fed state possibly due to the higher and inherently
more variable concentrations present. A similar comparable analysis is
not available in the literature and the finding potentially has interesting
implications. Bioavailability and bioequivalence studies are normally
performed in the fasted state, the difference between subject A and B
(Fig. 9) indicate a possible reason for subject specific variation during
these studies. The behaviour also supports the suggestion (section 3.5)
of applying a simulated media recipe that matches the low factor
concentration and pH values to determine a worst case solubility value.
Since the majority of individuals (approximately 90%) will have fluid
compositions with factor concentrations and pH values greater than this
point.
The time dependent compositional changes could be viewed as si-
milar to the gastric transfer process [54] where a drug is exposed to a
rapid change in physicochemical environment that can induce pre-
cipitation. Albeit in this case the change is not anatomical and based on
the results will be of transient duration with a return to the original
P
ho
sp
ho
lip
id
 (m
M
)
0.01
0.1
1
10
Total Bile Salt (mM)
0.1 1 10
Fr
ee
 F
at
ty
 A
ci
d 
(m
M)
0.1
1
10
Total Bile Salt (mM)
0.1 1 10
Ch
ol
es
te
ro
l (m
M)
10−3
10−2
10−1
1
Total Bile Salt (mM)
0.1 1 10
pH
2
4
6
8
Total Bile Salt (mM)
0.1 1 10
Fig. 9. Fasted data sample time analysis. Fasted
data;△ subject A; o subject B, see also Figure S2 a
and b.
K. Pyper, et al. European Journal of Pharmaceutics and Biopharmaceutics 153 (2020) 226–240
237
physicochemical conditions or even a higher solubility environment.
Further analysis will be required to define the exact nature of these
findings and changes, but if possible these should be factored into
methods designed to explore supersaturation and precipitation [55].
4. Conclusions
This is an initial investigation applying a novel mathematical ana-
lysis treating HIF as a five dimensional fluid using a published HIF
composition data set in both the fasted and fed states. None of the five
variables analysed (total bile salt, phospholipid, free fatty acid, cho-
lesterol and pH) follow simple statistical distributions. The amphiphilic
variable (bile salt, phospholipid, free fatty acid and cholesterol) con-
centrations are positively correlated indicating that statistically de-
signed simulated intestinal fluid compositions may require adjustment
to remove non-biorelevant combinations. The analysis calculates for
both fasted and fed states up to eight points that provide a> 95%
statistical coverage of HIF compositional variation and could be used as
a guide to link in vitro measurements to in vivo data. This indicates that
a single point (depending upon the type of drug) could be applied as a
worst-case scenario for in vitro estimation of BCS/DCS solubility clas-
sification. The analysis also determines that on a short time scale a
variable’s average rate of change in either prandial state is zero with the
average Euclidean distance between points greater in the fed than in the
fasted state. This result, in combination with the overall statistical
analysis, indicates that there are boundaries to HIF variability, espe-
cially in the fasted state. Further time-based analysis is required to fully
examine the data, relate variable concentrations to time over a longer
period and investigate the physiology of the fed state where digestion
and absorption are occurring.
The mathematical analysis applied is scalable and further data sets
could be added to refine the statistical estimation, along with the ap-
plication to different fed states [46], disease states [56] or specific
patient age groups [57]. A consistent approach to the HIF components
analysed between studies would assist, along with (from a drug solu-
bility perspective) identification and ranking of the component’s solu-
bility impact using DoE or related statistical approaches. Linkage of the
compositional space to the physical characteristics of HIF would also
provide further insights. The calculated ellipsoid boundary points can
guide the development of statistically relevant SIF recipes that explore
intestinal solubility space. However, this requires further experimental
studies to compare drug solubility performance with these systems
against published results in this space. Overall, this approach has re-
vealed interesting insights into HIF composition with multiple im-
plications for future studies in this research area and indicates that this
general approach might be a fruitful research avenue to explore for an
increased understanding of this complex fluid.
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